Annovis Bio Inc (ANVS NYSE) stock market data APIs
$2.0757
-0.06(-2.9%)
as of May 15, 2026
Try our APIs with
free plan!
Annovis Bio Inc Financial Data Overview
Price chart is built with
Anychart
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Prev. Close
2.0757
Open
2.0171
High
2.1029
Low
2.0081
52 wk Range
1.54-5.5
Market Cap
71 373 K
Shares Outstanding
34 647 K
EPS
-0.63
Beta
1.258
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Annovis Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Annovis Bio Inc data using free add-ons & libraries
Get Annovis Bio Inc Fundamental Data
Annovis Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Annovis Bio Inc News
New
Annoivs Bio Launches $10M Underwritten Offering
(RTTNews) - Annovis Bio, Inc. (ANVS) announced a $10 million underwritten public offering of common stock and accompanying warrants. The offering is expected to provide additional capital to support t...
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational or...
The Credibility Filter Wall Street Uses to Sort Biotech Winners
VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one...
Annovis Strengthens Patent Portfolio With Buntanetap, Stock Up
(RTTNews) - Shares of Annovis Bio, Inc. (ANVS) are up by 17% after the company announced that it has secured a new U.S. patent for its lead drug candidate, Buntanetap, expanding its potential use in p...
Get Annovis Bio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
